A phase II randomized open-label trial of biweekly pemetrexed plus gemcitabine versus pemetrexed or pemetrexed plus carboplatin in relapsed non small cell lung cancer after neoadjuvant or adjuvant chemotherapy

Trial Profile

A phase II randomized open-label trial of biweekly pemetrexed plus gemcitabine versus pemetrexed or pemetrexed plus carboplatin in relapsed non small cell lung cancer after neoadjuvant or adjuvant chemotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2010

At a glance

  • Drugs Carboplatin; Gemcitabine; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Aug 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Oct 2009 Status changed from not stated to active, no longer recruiting.
    • 05 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top